Skip Navigation

European Journal of Heart Failure 2002 4(2):215-219; doi:10.1016/S1388-9842(01)00207-0
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Korewicki, J.
Right arrow Articles by Rywik, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Korewicki, J.
Right arrow Articles by Rywik, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2002 European Society of Cardiology

Management of heart failure patients in Poland

J. Korewickia,*, S. Rywikb and T. Rywika

a II Department of Valvular heart Disease, Stefan Cardinal Wyszynski National Institute of Cardiology, Alpejska str.42, 04-828 Warszawa, Poland
b Department of Epidemiology and Prevention of Cardiovascular Diseases, Stefan Cardinal Wyszynski National Institute of Cardiology, Alpejska str.42, 04-828 Warszawa, Poland

* Corresponding author. Tel.: +48-22-8154216; fax: +48-22-8153298. E-mail address: jkorewicki{at}ikard.waw.pl, plmncwwa{at}ikard.waw.pl


  Abstract

Over the next 10 years, heart failure is likely to become a medical and sociological problem as a result of improved treatment of ischaemic heart disease and hypertension. At present, in Poland, there are only 50% of the cardiological or cardiac surgery procedures (coronarography, PTCA, CABG, surgery of congenital or acquired heart disease) performed compared to Western Europe. After being registered on the waiting list, it can take anything between 3 and 12 months before the procedure is done. Patients with heart failure have diagnostic tests such as ECG, chest X-ray, and biochemical evaluation performed regardless of the level of care. When echocardiography, exercise testing or Holter monitoring is required, it is done at specialist or reference specialist facilities with a waiting time of approximately 1–3 months. Pharmaceutical treatment of CHF is also inadequate. ACE inhibitors are prescribed in approximately 68% of patients. The average prescribed dosage is far from that recommended in guidelines. Only 18–29% of patients with HF are on beta blockers. The improvement of cardiological care standards depends mainly on the financial resources of State Health System Agencies.

Key Words: Heart failure • Management • Health care services

Received October 11, 2000; Revised July 20, 2001; Accepted September 10, 2001


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur J Heart FailHome page
F.D. R. Hobbs, J. Korewicki, J. G.F. Cleland, J. Eastaugh, N. Freemantle, and on behalf of the IMPROVEMENT Investigators
The diagnosis of heart failure in European primary care: The IMPROVEMENT Programme survey of perception and practice
Eur J Heart Fail, August 1, 2005; 7(5): 768 - 779.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
T. Jaarsma, F. M. Haaijer-Ruskamp, H. Sturm, and D. J. Van Veldhuisen
Management of heart failure in The Netherlands
Eur J Heart Fail, March 16, 2005; 7(3): 371 - 375.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.